Patients
The Precision Cancer Medicine Registration Study of Omics Data from
Genomic Information Analysis Leading to New Effective Therapy with
FoundationOne CDx (PROFILE-F) was a prospective observational study
conducted to characterize genomic aberrations and their clinical utility
using genomic profiling. Thirteen pediatric and AYA cases with advanced
solid tumors at our hospital who progressed or became resistant to
standard systemic therapy were enrolled in this study. These patients
underwent CGP between November 2017 and December 2019 under the
PROFILE-F study. The PROFILE-F study was approved by the institutional
review board of Tokyo Medical and Dental University (TMDU) (approval
#G2018-002).